Ceramide Synthase 6 Mediates Triple-Negative Breast Cancer Response to Chemotherapy Through RhoA- and EGFR-Mediated Signaling Pathways

PURPOSE: Limited treatment options and lack of treatment sensitivity biomarkers make the clinical management of triple-negative breast cancer (TNBC) challenging. Ceramide synthase 6 (CERS6) generates ceramides, which are key intermediates in sphingolipid biosynthesis and play important roles in canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hui, He, Bin, Ke, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807320/
https://www.ncbi.nlm.nih.gov/pubmed/36479603
http://dx.doi.org/10.4048/jbc.2022.25.e47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807320/
https://www.ncbi.nlm.nih.gov/pubmed/36479603
http://dx.doi.org/10.4048/jbc.2022.25.e47

Ejemplares similares